clinical trial · NCT07187375
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
Congenital Adrenal HyperplasiaCrinecerfont
brief summary
The main objective for this study is to evaluate the pharmacokinetics (PK) of crinecerfont in pediatric participants 0 to \<2 years of age with congenital adrenal hyperplasia (CAH).
started
Sep 30, 2025
primary completion
Sep 6, 2029
completion
Oct 4, 2029
last updated
Jun 16, 2026
official title
A Phase 2, Open-Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Crinecerfont in Pediatric Subjects 0 to <2 Years of Age With Congenital Adrenal Hyperplasia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol